Prediction of the efficacy of exenatide treatment in suboptimally controlled type 2 diabetic patients by Metabolic Fingerprint” and evidence-based KADIS® decision support: a clinical pilot trial - KADIS-Byetta

Institute of Diabetes Gerhardt Katsch”0 个研究点目标入组 72 人开始时间: 2009年4月24日最近更新: 2012年12月10日

适应症

试验速览

暂无简介。

•type 2 diabetes, age = 30 < 70 y, diabetes duration = 1 and = 12 y, A1c = 7.0 and = 8.5%
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•preceding ketoacidosis or lactic acidosis, severe hypoglycaemic episodes, existing cardiac or haematological diseases, severe hypertension, hepatic and renal disease (macroalbuminuria or diabetic nephropathy, severe diabetic neuropathy, existing gastrointestinal disease, acute or chronic inflammatory disease, established foot ulceration, drug taking to promote weight reduction, treatment with insulin, thiazolidinediones or meglitinides prior to inclusion examination, therapy with corticosteroids, drugs known to have gastrointestinal effects, psychological disorder, lactation and pregnancy, subjects who are not able to understand written and verbal instructions, unwillingness of blood taking, participation in a clinical trial during the last 2 months prior to the study, hypersensitivity reactions against medicinal product

发起方

Institute of Diabetes Gerhardt Katsch”